

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT.



Regulated information

End of the stabilization period, non-exercise of the over-allotment option

Brussels, Belgium, 14 June 2016 – ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces the end of the stabilization period in relation to its initial public offering on the Euronext Brussels and Euronext Paris regulated markets (the “Offering”) and the non-exercise of the over-allotment option.

The Company had granted to KBC Securities NV/SA (“KBC Securities”), as stabilization manager (the “Stabilization Manager”), on behalf of Société Générale and KBC Securities, an over-allotment option to subscribe to a maximum of 335,000 additional new shares at the Offer price of EUR 7.00 and to cover over-allotments or short positions resulting from any over-allotments in connection with the Offering (“Over-Allotment Option”). The Over-Allotment Option was exercisable for a period of 35 days as from the first day of trading of the shares on the regulated markets of Euronext Brussels and Euronext Paris (i.e. until 15 June 2016).

Once, during the price stabilization period, the Stabilization Manager, on behalf of Société Générale and KBC Securities, had purchased on the market an identical number of shares to the number made available, it indicated that the Over-Allotment Option would not be exercised and that it would therefore not be subscribing to any new shares in this respect.

Subsequently, the total number of shares issued within the framework of the Offering remains 3,350,000, representing total gross proceeds of approximately EUR 23.5 million.

Following the Offering, ASIT biotech’s share capital is EUR 17,438,592.81 represented by 12,756,800 shares. For an overview of the dilution resulting from the Offering, see the “Principal Shareholders” section of the prospectus (the “Prospectus”) prepared by the Company in connection to the Offering, which is available on the Company’s website (www.asitbiotech.com).

The stabilization period began on 11 May 2016 and ended on 9 June 2016.

In accordance with article 9(3) of EU Regulation No. 2273/2003 and article 5, §2 of the Belgian Royal Decree of 17 May 2007, KBC Securities, as Stabilization Manager, reports the details of the stabilization activity carried out in the appendix.

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen:

gp-ASIT+™ and house dust mite: *hdm-ASIT+™*), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

Contact

Company

Thierry Legon, CEO
ASIT biotech
Tel. +32 2 264 03 90
investors@asitbiotech.com

Media and Investor Relations - France

NewCap
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu

Media Relations - Belgium

Laure-Eve Monfort
Tel.: +32 2 290 90 93
monfort@comfi.be

Appendix

The stabilization transactions were carried out under the following conditions:

Date of stabilization trades	Price range of stabilization trades (EUR)	Number of shares purchased
11/05/2016	6.500 – 6.950	53,223
12/05/2016	6.400 – 6.890	13,277
13/05/2016	6.301 – 6.750	28,374
16/05/2016	6.310 – 6.700	3,636
17/05/2016	6.252 – 6.400	7,040
18/05/2016	6.190 – 6.545	32,020
19/05/2016	6.350 – 6.788	4,950
20/05/2016	6.500 – 6.779	740
23/05/2016	6.500 – 6.758	2,022
24/05/2016	6.600 – 6.760	2,718
25/05/2016	6.250 – 6.749	55,150
26/05/2016	6.649 – 6.739	350
27/05/2016	6.500 – 6.747	1,012
30/05/2016	6.677 – 6.700	1,188
31/05/2016	6.552 – 6.699	4,343
01/06/2016	6.643 – 6.700	3,800
02/06/2016	6.550 – 6.700	5,470
03/06/2016	6.450 – 6.700	13,335
06/06/2016	6.500 – 6.699	23,531
07/06/2016	6.500 – 6.700	19,006
08/06/2016	6.500 – 6.700	21,328
09/06/2016	6.300 – 6.650	38,487
TOTAL		335,000

Forward Looking Statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,”

“intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Important Legal Notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.